Frontiers in medicine · 2025
Case Report: Mycoplasma pneumoniae-induced rash and mucositis in a child.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mo Xiaoying, Wang Meihua, Jiang Xue, Jin Li
Аннотация
RATIONALE: Mycoplasma pneumoniae (MP) is a common pathogen responsible for pediatric community-acquired pneumonia. MP infection can also induce extrapulmonary manifestations, including mucocutaneous eruptions. Mycoplasma pneumoniae-induced rash and mucositis (MIRM) is a relatively newly described entity distinct from erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). However, MIRM remains underrecognized, with limited cases reported in China.
PATIENT CONCERNS: A previously healthy 10-year-old boy presented with fever, cough, severe mucositis (oral and ocular involvement), and disseminated rash for 5 days.
DIAGNOSES: The patient was diagnosed with Mycoplasma pneumoniae-induced rash and mucositis (MIRM), confirmed by clinical presentation and laboratory detection of MP nucleic acid.
INTERVENTIONS: The treatment regimen for the patient included intravenous azithromycin, methylprednisolone at a dosage of 1 mg/kg/day, intravenous immunoglobulin (IVIG), vitamin C, oral antihistamines, topical treatments for mucosal care, ophthalmic ointment, and calamine lotion. After 1 week, due to a persistent cough and a positive Mycoplasma pneumoniae (MP) nucleic acid test, the patient's treatment was transitioned to oral doxycycline.
OUTCOMES: The patient experienced significant clinical improvement after 14 days, with resolution of rash, mucosal lesions, and cough. Follow-up tests confirmed clearance of MP nucleic acid and normalization of inflammatory markers.
LESSONS: MIRM is a distinct mucocutaneous entity associated with MP infection. Pediatricians should recognize its clinical presentation early to provide prompt targeted therapy and supportive care, thus preventing complications.
PATIENT CONCERNS: A previously healthy 10-year-old boy presented with fever, cough, severe mucositis (oral and ocular involvement), and disseminated rash for 5 days.
DIAGNOSES: The patient was diagnosed with Mycoplasma pneumoniae-induced rash and mucositis (MIRM), confirmed by clinical presentation and laboratory detection of MP nucleic acid.
INTERVENTIONS: The treatment regimen for the patient included intravenous azithromycin, methylprednisolone at a dosage of 1 mg/kg/day, intravenous immunoglobulin (IVIG), vitamin C, oral antihistamines, topical treatments for mucosal care, ophthalmic ointment, and calamine lotion. After 1 week, due to a persistent cough and a positive Mycoplasma pneumoniae (MP) nucleic acid test, the patient's treatment was transitioned to oral doxycycline.
OUTCOMES: The patient experienced significant clinical improvement after 14 days, with resolution of rash, mucosal lesions, and cough. Follow-up tests confirmed clearance of MP nucleic acid and normalization of inflammatory markers.
LESSONS: MIRM is a distinct mucocutaneous entity associated with MP infection. Pediatricians should recognize its clinical presentation early to provide prompt targeted therapy and supportive care, thus preventing complications.